Last updated on March 2010

Effects of Raltegravir (Isentress ) on Lipid and Carbohydrate Metabolism and Mitochondrial Function in Healthy Volunteers

Brief description of study

Raltegravir is the first of a new antiretroviral class. A better profile of metabolic toxicity is expected. In order to better define its effects, without interference with other drugs, a study on healthy volunteers is warranted.

Clinical Study Identifier: NCT00772720

Contact Investigators or Research Sites near you

Start Over

Hospital Clinic

Barcelona, Spain
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.